Fundraising Fox

HBM Partners

Crossover fund

Zug · Pre-Seed–Late Stage · 6 people tracked

Find your way into HBM Partners

356 people in our graph share verified history with the HBM Partners team — schools, employers, funds. One of them is your warm intro.

Bastian Hasslingerunlockedknows Shirin Schneeberger · together at ETH Zürich (overlapped)
×2knows the team · via Harvard Medical School
×3knows the team · via ETH Zürich
×4knows the team · via Freie Universität Berlin
×2knows the team · via Stanford University
Fox Verdict
Sign up to see your fit

Investment thesis

HBM Partners invests in private and public healthcare companies across venture, growth and buy-out financings. It targets the biopharma, medtech, diagnostics and broader healthcare sectors in Europe and North America, as well as India, China and other emerging markets. The firm supports portfolio companies through all stages of development, aiming to add value through its industry experience and global network. Regulated by FINMA, HBM Partners advises the SIX-listed HBM Healthcare Investments Ltd and several specialised public and private equity funds, and has a track record of over 100 investments resulting in more than 60 trade sales and IPOs.

Source: firm website, verified Aug 3, 2026.

Stage
Pre-Seed–Late Stage
Check
$5M – $50M
HQ
Zug, CH
Instruments
Equity
Founded
2001
AUM
$2.1B
Tracked investments
4

Team · 6 people

from the firm's website & curated & public directories
Francesco D'Amico· Board, Chairman
Francesco D’Amico· Chairman

Serves as Chairman of the Board at HBM Partners.

Founder mafia

2 people who came through HBM Partners went on to found or lead other companies.

What they invest in

from 4 of 4 portfolio companies

Biotech ×4AI & Machine Learning ×2Deep Tech ×2Healthtech ×2Digital Health ×1Medical Devices ×1

HQs:United States×3Switzerland×1

Investments · 4 tracked

founders shown can be your intro path

By year:2022 · 12016 · 12 dated

Monte Rosa Therapeuticsmonterosatx.comin𝕏NASDAQ: GLUE✓ verified

Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets.

AI & Machine LearningBiotechDeep TechHealthtechBoston, US

Markus Warmuth(M.D., Chief Executive Officer)inSharon Townson(Ph.D., Chief Scientific Officer)inJohn Castle(Ph.D., Chief Data and Information Officer)inFilip Janku(M.D., Ph.D., Chief Medical Officer)inPhil Nickson(Ph.D., J.D., Chief Business and Legal Officer)inMagnus Walter(DPhil, Chief Technology Officer)in

Co-investorsAisling CapitalNew Enterprise Associates (NEA)Versant VenturesAmzak HealthAvoro Capital AdvisorsGV (Google Ventures)+1 more

Swixx Biopharmaswixxbiopharma.comin✓ verified

Swixx BioPharma is a specialized pharmaceutical distributor and market access partner that represents international biopharma, OTC, and medical device companies in markets across Central & Eastern Europe, the Middle East, North Africa, Latin America, and Eurasia.

BiotechHealthtechMedical DevicesBaar, CH

Co-investorsBain Capital Life SciencesMérieux Equity PartnersSK Capital Partners

Neuron23neuron23.cominMar 2022 · $100M

Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease.

AI & Machine LearningBiotechDeep TechDigital HealthSouth San Francisco, US

Nancy Stagliano(CEO)in

Co-investorsKleiner PerkinsSoftBank GroupSoftBank Vision FundWestlake Village BioPartnersACORN BIOVENTURESCowen Healthcare Investments+1 more

Symbiomix TherapeuticsApr 2016

BiotechNewark, US

Robert Jacks(Executive Officer)Joseph Amprey(Executive Officer)in

BoardRishi Gupta(Director)inKlaus Veitinger(Director)inThomas Beck(Director)Ben Auspitz(Director)

Co-investorsF-Prime CapitalHBM Healthcare InvestmentsOrbiMed

Exits · 1

IPOs and acquisitions across the tracked portfolio

Monte Rosa TherapeuticsNASDAQ: GLUE

Portfolio news

latest coverage across their companies

Frequently asked questions

What stage does HBM Partners invest at?
HBM Partners invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is HBM Partners's typical check size?
HBM Partners typically writes checks of $5M – $50M.
What sectors does HBM Partners focus on?
HBM Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is HBM Partners located?
HBM Partners is headquartered in Zug, CH.

Co-investors · 8

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M
New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

$200K – $40M
OrbiMed

OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 1
$1M – $75M
Versant Ventures

Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.

$250K – $5M
Aisling Capital

Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.

SR One Capital Management

SR One is a biotechnology-focused venture capital firm that partners with founders to develop innovative science into new medicines.

Pontifax Venture Capital

Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.

$6.3M – $128M
Lilly Asia Ventures

Lilly Asia Ventures (LAV) is a biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto, backing entrepreneurs building companies focused on breakthrough products that treat disease and improve human health.

Firms observed investing alongside HBM Partners, from public investor directories. Shared companies are the overlap with HBM Partners's recorded portfolio.

Similar investors

Featured in lists